Peptide API and GLP-1 CDMO Risk / Opportunity Ranking

Thesis: Medtide has direct evidence of meaningful peptide API capacity expansion in both China and the U.S., which supports a durable 1 year+ growth case in peptide CRDMO services.

Why now: Recent evidence says the Hangzhou expansion was completed in H2 2025 and the Rocklin, California site retrofitting started in H2 2025, with the expansion highlighted again in May 2026 article context, making the growth capacity newly available or nearing availability for the forecast horizon. Article reported on May 16, 2026 and May 17, 2026 for the update summaries.

Caveats: Most positive evidence comes from repeated coverage of the same recognition/expansion story rather than multiple independent company events. Several operational facts are kept as undated or dated evidence, so exact publication timing for some claims is less certain. External CPC/DMF context is article-level and weaker than direct Medtide event evidence.

Thesis: WuXi Biologics has the strongest direct positive evidence in the screen: multiple recent facility completions, capacity additions, GMP releases, and regulatory certifications across Singapore, Chengdu, Shanghai, South Korea, and Brazil-linked vaccine manufacturing. This supports durable multi-year capacity and execution momentum.

Why now: Recent company-specific milestones are dense and current: Singapore DP topping-out on June 4-5, 2026 with 120,000L added capacity and ~100M units/year expected output

Caveats: Most direct evidence is biologics/CDMO rather than peptide-specific. Some policy-risk context in the reviewed sources refers to WuXi AppTec, not WuXi Biologics; those should not be conflated.

Thesis: CordenPharma shows strong long-horizon opportunity from consolidating peptide API capacity via AmbioPharm, adding US and China sites, complementary synthesis capabilities, and a broader peptide platform during sustained GLP-1 demand.

Why now: The acquisition agreement announced on May 27, 2026 and reinforced by follow-up reporting through June 1, 2026 creates a durable business-state change: expanded footprint, strengthened US manufacturing, and broader peptide synthesis options

Caveats: Some favorable capacity context in the reviewed sources comes from supporting source pages or supporting article context and is weaker than direct event evidence.

Thesis: AmbioPharm has clear strategic value as peptide API capacity, evidenced by CordenPharma's agreement to acquire it specifically to expand global peptide API manufacturing and strengthen US and China supply options.

Why now: The key timing catalyst is the late-May 2026 acquisition agreement by CordenPharma, which reframes AmbioPharm as strategic peptide infrastructure in a tight-capacity market as of May 27, 2026 to June 1, 2026

Caveats: Most evidence is deal-announcement driven and repeated across wire duplicates rather than post-close operating updates. Some expansion references in supporting context are undated or outside clear recency proof and should be treated cautiously.

Thesis: OneSource has one of the strongest explicit growth outlooks in the screen, with direct evidence tying its CDMO/GLP-1 generics exposure to a jump from FY25 revenue of $170M to FY28 guidance of $500M and 40% EBITDA margins.

Why now: A recent May 2026 article frames April 21, 2026 regulatory approval as a key catalyst and links that catalyst to the FY28 growth outlook, which is directly relevant for a 1 year+ horizon.

Caveats: The core opportunity case depends heavily on a single article and company guidance. The article also notes trailing EV/EBITDA above 50x and only forward valuation easing, which suggests expectation risk, though this is contextual not negative evidence. Ticker is blank in the required company list, so output preserves reviewed sources input.

Thesis: Hovione has the strongest positive reviewed sources evidence in this screen: on May 11, 2026 it announced its intranasal drug-delivery platform reached a milestone with a lead single-use nasal dry powder device now available for commercial partnerships, and the article also says device design and manufacturing capability were established with initial patent grants; additionally, a later article dated June 17, 2026 reports Hovione acquired a formulation facility adjacent to its Loures plant to boost inhalation and oral dosage capabilities. Together these point to active capability expansion and commercialization optionality over a 1 year+ horizon

Why now: The evidence is both recent and sequential: platform commercialization readiness was reported on May 11, 2026, then a formulation facility acquisition was reported on June 17, 2026, suggesting continuing capability buildout rather than a one-off mention

Caveats: The IDC relation is context only and cannot be used for counterparty propagation. The acquisition article has limited detail and financial terms were undisclosed.

Thesis: MPP has strong direct positive evidence of commercial relevance: a three-year development and manufacturing agreement signed May 11, 2026 with Vector Science & Therapeutics for peptide formulations, plus joint development of 22 novel shelf-stable peptide formulations and access to an FDA-registered cGMP facility in Mequon, Wisconsin. Additional evidence says LyoGenesis Plus entered an agreement to acquire MPP, suggesting strategic value and potential support for expansion.

Why now: Why now is strong because the manufacturing agreement was announced on May 11, 2026 and acquisition-related access/ownership developments followed on May 13, 2026 to May 14, 2026 source dates, making this a recent business-state change that can matter over 1 year+.

Caveats: Several supporting rows are undated evidence and should be treated cautiously on recency. A number of reviewed sources rows repeat the same underlying announcement and are not independent confirmation. No direct business performance disclosure for MPP itself.

Thesis: PharmaBlock has direct evidence of commissioning its first peptide GMP pilot-scale plant, expanding into peptide CDMO capacity with concrete SPPS infrastructure that can matter over a 1 year+ horizon.

Why now: The facility became operational in early June 2026, making it a fresh capacity catalyst for the next year.

Caveats: Only two closely related articles support the thesis, so breadth of corroboration is limited. Evidence is about plant commissioning, not yet utilization, contracts, or margin impact. Coverage confidence is lower than for large public peers in the screen.

Thesis: Asymchem has favorable long-horizon opportunity from verified peptide and oligonucleotide capacity expansion: over 45,000 L SPPS reactor volume, annual peptide capacity above 22.5 metric tons, and planned expansion to about 69,000 L by end-2026.

Why now: The timing is driven by the April 14, 2026 unveiling of Asymchem's integrated TIDES commercial supply matrix and explicit end-2026 capacity target, which fits a 1 year+ rollout and commercialization horizon

Caveats: Coverage confidence is lower than for larger names because only a small number of direct company articles were available. Several supporting context items are weaker article-level support and should not be treated as equivalent to direct operating disclosures. No direct adverse company-specific event evidence was available.

Thesis: Zydus has the strongest positive multi-catalyst setup in the reviewed sources: completed Assertio acquisition for a US oncology platform, FDA Priority Review for saroglitazar with a Nov. 27, 2026 PDUFA, planned US launch by March 2027 if approved, buyback support, and biosimilar optionality.

Why now: This is a classic chronology-driven 'why now': acquisition announced in May 2026 and completed by June 16-17, 2026; saroglitazar received Priority Review on May 28, 2026 with a clear PDUFA date and launch path into 2027

Caveats: One high deterministic positive row came from a trade-agreement article not actually specific to Zydus fundamentals; it was not relied on for the thesis. Some biosimilar/market expansion evidence is sector-level and weaker than the direct company-specific acquisition and FDA review events. Semaglutide supply-chain and safety commentary is material but still more contextual than a direct adverse company event.

Thesis: Cambrex has the strongest opportunity setup in the screen because the reviewed sources includes direct positive evidence of a sizable manufacturing expansion in Iowa, plus recent company-context evidence that it offers custom peptide synthesis across SPPS/LPPS and large-scale GMP manufacturing. For a 1 year+ horizon, capacity expansion and peptide manufacturing capability are durable positives.

Why now: Recent evidence within the recent evidence window includes a May 19, 2026 article stating Cambrex Charles City will spend $150 million and create 104 jobs tied to Iowa incentives

Caveats: The strongest positive row is one article/event; same-article repeats are not independent confirmation. Some older supportive peptide-expansion context from 2025 was excluded by the 90-day recent evidence window and should not drive the current score. No direct customer win, utilization, or profitability evidence is provided.

Thesis: Bachem has direct positive financing evidence inside recent evidence window: on April 27, 2026 it closed a CHF 500 million revolving credit facility with five-year maturity and an option to increase by CHF 150 million, explicitly to refinance lines and support strategic growth initiatives. That financing flexibility aligns with peptide/CDMO scale-up potential over a 1 year+ horizon.

Why now: The why-now rests on the fresh April 27, 2026 financing close, which is later-dated and directly tied to strategic growth. Recent supporting context also points to strong GLP-1 manufacturing demand and tight peptide capacity in 2026, though that is weaker than the financing event.

Caveats: Most GLP-1-specific upside evidence in the reviewed sources are external/company-context, not direct event evidence. Some industry-growth context is article-level and should not be over-weighted.

Thesis: Merck KGaA has the strongest positive evidence set in the screen: it raised 2026 guidance, reported strong Life Science growth, and announced the $11.3 billion acquisition of Bio-Techne, which management says should be immediately accretive to sales growth and EBITDA pre margin with EPS accretion by year 3 and about EUR 140 million annual cost synergies by year 3

Why now: Why now is strong because the positive evidence is recent and sequenced: Q1 guidance raise and segment strength in mid-May 2026 were followed by the June 25-26, 2026 acquisition announcement for Bio-Techne, creating a fresh strategic repositioning catalyst for the next year and beyond.

Caveats: Many M&A rows are same-event repetitions, not independent confirmation. Some positive supporting items are undated or supporting article context.

Thesis: LyoGenesis Plus has the strongest positive setup in the screen because dated May 2026 evidence says it agreed to acquire MPP Group, an FDA-registered cGMP CDMO, which would add peptide manufacturing capability, a 35,000 sq ft facility, and support access to multiple peptide formulations. Supporting facts also indicate financing capacity via a $2 million equipment line of credit and a $1 million accounts receivable facility.

Why now: The key evidence is recent within the 90-day recent evidence window: articles crawled/published around May 13, 2026 to May 14, 2026 describe the option investment and the MPP acquisition agreement, making this a live strategic-buildout story that can matter over a 1 year+ horizon.

Caveats: Several positive rows are repeated from the same underlying transaction and are not independent confirmation. Part of the evidence is undated at the row level even though representative articles have May 2026 source dates. Opportunity depends on successful acquisition integration and execution.

Thesis: Thermo Fisher has strong direct evidence of Q1 2026 earnings beat, raised FY2026 guidance, and strategic portfolio actions, supporting a durable large-cap opportunity case with biopharma services relevance.

Why now: The key why-now is the April 2026 earnings and guidance reset, followed by the April 2026 microbiology divestiture announcement, both recent enough to shape the next 1 year+ operating profile.

Caveats: The divestiture rows are labeled neutral in polarity, so they support strategic change more than automatically positive value creation. Many additional rows are low-signal institutional ownership updates and should not be overweighted.

Thesis: Bachem has a credible long-horizon opportunity profile because multiple 2026 market reports place it among key peptide and oligonucleotide CDMO players, and one report references a May 2025 capital investment. Broader market forecasts cited in dated 2026 articles indicate sustained growth in peptide synthesis and related CDMO demand, which fits Bachem's positioning, though the reviewed sources lack a strong direct company operating milestone inside the recent evidence window.

Why now: Why now is decent because the dated 2026 articles reinforce Bachem's inclusion in expanding peptide and oligonucleotide markets, and a Capital Markets Day is scheduled for November 26, 2026, which may become a later information catalyst, though it is not itself a positive operating event.

Caveats: Much of the evidence is market-report or company-group-linked context, not direct company operating evidence. Some positive rows are not directly grounded to Bachem-specific events. Capital Markets Day evidence is neutral, not directional proof.

Thesis: Recent company-context evidence supports Zhejiang Peptites as a scaled peptide CRO/CMO/CDMO with broad product coverage, certifications, and export reach. A May 27, 2026 company page describes 60+ peptide APIs covering obesity and diabetes, multiple products filed/approved in multiple countries, annual peptide powder capacity of 8,000 kg and liquid capacity of 2,000 tons, plus claimed U.S. FDA and other certifications. While this is supporting article context rather than a direct dated event, it is recent and relevant for a 1 year+ opportunity lens.

Why now: The main reason now is recency: the May 27, 2026 company page presents current manufacturing scale, certifications, obesity/diabetes peptide product breadth, and global export positioning within the recent evidence window.

Caveats: Evidence is primarily article-level/company-site context, not direct event/facts. Market research mention from October 28, 2024 is outside recent evidence window and weaker than current company-specific proof. No direct customer, contract, or financing event in the recent evidence window.

Thesis: Lonza has strong direct evidence of strategic sharpening into a pure-play CDMO, confirmed 2026 outlook, new platform licensing deals, and capacity investment in high-value modalities, supporting a durable 1 year+ opportunity case.

Why now: Recent May-June 2026 evidence shows confirmed FY2026 guidance, pure-play CDMO transformation, strategic platform licensing, and ADC capacity investment. Later dated June evidence can supersede older status claims and supports that the repositioning is active now.

Caveats: Some direct_positive_evidence in the reviewed sources are linked to counterparties rather than Lonza itself; this assessment relies only on clearly Lonza-relevant direct evidence. Several negative rows are context-prone and not strong direct company-specific adverse events.

Thesis: Recent company-site evidence supports JYMed as a peptide-focused manufacturer with meaningful semaglutide and GMP positioning. A April 28, 2026 article says a second semaglutide DMF was listed by the U.S. FDA as available for reference after completeness assessment. A May 9, 2026 page describes peptide-only CRO/CDMO services from early-stage to commercial production, and other recent company pages describe ten cGMP lines and 30,000 L SPPS/LPPS reactor volume, though those are not positive evidence.

Why now: Why now is tied to the recent April 28, 2026 semaglutide DMF availability statement and the May 9, 2026 CRO/CDMO page, both within the recent evidence window and relevant to commercial peptide readiness over a 1 year+ horizon.

Caveats: Evidence is primarily article-level/company-site context rather than direct positive events. Some capacity and facility claims come from pages dated before recent evidence window or from undated context. No direct contracts, financing, or customer wins in the recent evidence window.

Thesis: PolyPeptide's opportunity case is mainly driven by credible takeover interest: Swissinfo reported the company shortlisted EQT and IDG for the next bidding round, with Altaris also pursuing, while the article also notes PolyPeptide specializes in peptide therapies and has manufacturing sites in Europe, the US, and India.

Why now: Why now is the May 2026 report of shortlisted bidders, supplemented by a June 2026 analyst target increase to CHF40 from Barclays. Those are near-to-medium-term catalysts, but the 1 year+ fit is only medium because the reviewed sources lack hard operational milestones beyond strategic interest

Caveats: Most non-M&A support is market-report or analyst-context evidence. Takeover interest is not the same as a signed transaction.

Thesis: Harbin Jixianglong faces a strong adverse regulatory thesis after the FDA warning-letter episode tied to relabeling semaglutide from an unapproved facility, which can impair trust, compliance standing, and export credibility over a 1 year+ horizon.

Why now: The main adverse evidence is recent, with the BioSpace article dated May 20, 2026 and external FDA warning-letter context dated May 19, 2026, so the issue is current rather than stale.

Caveats: Relations to semaglutide counterparties are context-only and not propagation evidence.

Thesis: Harbin has the clearest adverse evidence in the screen. The FDA warning-letter context says the firm identified itself as the manufacturer on API labels even though the API had been purchased from another firm, and specifically states that certain semaglutide API batches were manufactured by other firms, not Harbin. BioSpace summarizes this as relabeling APIs from another site in a potential attempt to circumvent GLP-1 import safeguards, published May 19, 2026, published May 20, 2026).

Why now: Why now is strong because the adverse evidence is recent, dated, and regulatory. The May 19-20, 2026 sequence indicates an active compliance issue with direct relevance to GLP-1 export credibility over the next year, May 19, 2026, May 20, 2026).

Caveats: Evidence comes from article-level supporting source context rather than positive or negative events. No operating impact is quantified in the reviewed sources. Even so, the regulatory context is direct and recent enough to dominate the risk view.

Thesis: The main thesis is regulatory and quality risk after FDA warning-letter coverage tied to refusing inspectors access and cited CGMP violations at a GLP-1 manufacturing facility.

Why now: The sole relevant article was reported on April 22, 2026, which is still within the recent evidence window and recent enough for a 1 year+ risk lens, but the reviewed sources lack a direct negative row and has limited follow-up evidence.

Caveats: The reviewed sources have no direct_negative_evidence row despite the adverse article summary, so conviction is lower than for Harbin Jixianglong. Only one article is present, limiting corroboration. Company appears private in this screen.

Thesis: Risk is dominant because multiple June and May articles show severe Q4 deterioration, revenue and margin pressure, North America weakness after Revlimid erosion, semaglutide ramp delays, and fresh USFDA Form 483 observations at a Hyderabad biologics facility.

Why now: The negative case is immediate and durable because the bad Q4 print surfaced in May/June 2026 and was followed by a June 26 report of seven USFDA observations, while semaglutide opportunity is present but not yet offsetting the earnings damage

Caveats: Some semaglutide opportunity evidence is offset by later evidence of slower ramp and inventory or regulatory friction. A portion of negative evidence references broad industry context, but the core risk thesis does not rely on that context-only material. The FDA observation article concerns a biologics facility, so direct propagation to peptide operations is not proven in the reviewed sources.

Thesis: WuXi has the clearest adverse thesis in the screen. Later-dated June 2026 evidence says the U.S. Department of Defense added WuXi AppTec to the Section 1260H/'Chinese military companies' list on June 8, 2026. Multiple articles say Pentagon contracting restrictions begin in June 2026 and indirect purchasing restrictions begin in 2027, while company-specific coverage says approximately 75% of sales are tied to U.S. business and existing customers have five years to wind down. WuXi sued the U.S. government on June 11, 2026, showing the issue is active rather than resolved. This later evidence supersedes the cleaner April earnings picture for risk ranking.

Why now: Why now is very strong because the key negative state change occurred on June 8, 2026 and was followed immediately by lawsuit and follow-on analysis from June 9 through June 25, 2026. That sequence is later than the positive April earnings releases and therefore decision-critical.

Caveats: Reviewed evidence includes some mislabeled entity fields in certain risk rows, but quoted article content clearly names WuXi AppTec. Some positive TIDES/capacity evidence is supporting article context, weaker than earnings and blacklist evidence.

Thesis: Risk is high because multiple later-dated earnings-related articles report an INR 176 crore impairment on intangible assets under development, FY26 revenue pressure from inventory destocking and slower early-stage order inflows, and a Business Standard article saying consolidated revenue fell 3%, EBITDA fell 28%, and the CDMO segment declined 10% in FY26. Those are direct adverse business indicators for the core thesis.

Why now: Why now is the April 28-29, 2026 earnings cycle, which clarified both the downside from FY26 weakness and the potential FY27 recovery path. That recent disclosure set is decision-critical and outweighs older generic membership context.

Caveats: Positive earnings rows in reviewed sources refer to Piramal Finance, not core pharma operations, and should not be over-propagated to pharma thesis. Several earnings articles are duplicates of the same disclosure and are not independent confirmation. Both opportunity and risk are real; this is a mixed evidence profile.

Thesis: Risk is somewhat higher than peers with undated evidence because the only cited support is explicitly stale, making current business state and competitiveness uncertain.

Why now: There is no current 'why now' in the reviewed sources. The only substantive item is dated July 17, 2018 and was excluded from retained evidence.

Caveats: No retained in-window evidence. The cited company description is materially stale for business-state assessment.

Thesis: The main risk is stale evidence coverage: the only cited company-context article is dated January 22, 2025 and was dropped by the 90-day recent evidence filter, leaving no current evidence base for present-state judgments.

Why now: Why now is weak because the reviewed sources' only specific article for BOC Sciences is outside the evidence recent evidence window and therefore not decision-usable for current-state ranking, coverage notes show 0 articles after recent evidence window).

Caveats: Low score reflects missing current evidence, not proven business weakness. No direct adverse event evidence exists. Outside-recent evidence window material cannot be used as current proof.

Thesis: Main risk is not an adverse event but the absence of in-window evidence. With no retained rows after recent evidence window, the reviewed sources cannot support a current positive thesis or confirm business momentum.

Why now: There is effectively no current 'why now' under the the evidence standard because the cited Protheragen press item was dated December 19, 2025 and excluded by the 90-day recent evidence window.

Caveats: Coverage after recent evidence window is zero rows. The excluded 2025 article cannot be used as current proof under the reviewed sources policy.

Thesis: The same recent evidence explicitly says TAPI can only offer and supply tirzepatide in countries and uses exempt from infringement, which constrains commercial scope and creates a meaningful thesis risk around addressable market and timing.

Why now: The relevant evidence is recent within the recent evidence window: a June 16, 2026 product page indicates TAPI offers tirzepatide API, but also states supply is limited to countries and uses exempt from infringement (article, June 16, 2026 ). That combination makes the name more timely than the others in this screen.

Caveats: The evidence is supporting article context from a single source and not an independently corroborated contract, capacity, or revenue event. Positive and negative points come from the same article and are not independent confirmation.

Thesis: Primary risk is lack of current evidence and uncertainty around whether a pilot-scale milestone has translated into ongoing commercial capacity, customers, or revenue-bearing production.

Why now: No in-window retained evidence supports a current catalyst. The cited pilot-scale milestone was dated December 31, 2025 and excluded by recent evidence window.

Caveats: Zero evidence retained after recent evidence window. Pilot completion alone, especially outside recent evidence window, is weaker than evidence of commercial conversion. No direct adverse evidence is present.

Thesis: Main risk is evidence staleness and lack of current confirmation of capacity, customers, or regulatory progress rather than a documented adverse development.

Why now: No current catalyst is supported in the retained reviewed sources evidence. The only cited item was April 27, 2025 and excluded by recent evidence window.

Caveats: Zero retained evidence after recent evidence window. The cited support is outside the allowed window for current ranking.

Thesis: No material adverse evidence is present either. Risk is minimal and reflects evidence absence rather than identified operational or financial problems.

Why now: Why now is unsupported because the only referenced article had a September 10, 2025 and was dropped by the 90-day recent evidence policy.

Caveats: No current source-cited evidence was found in the reviewed sources. The dropped source appears listing-style in any case, which would have been weaker than direct event evidence. Current status, contracts, and capability are not evidenced in-scope.

Thesis: There is also no direct negative evidence. A minimal risk score reflects the absence of current validated evidence rather than identified business stress.

Why now: Why now is unsupported because the only referenced article had a September 20, 2025 and was dropped by the 90-day recent evidence policy.

Caveats: No current source-cited evidence was found in the reviewed sources. Any claims from the dropped September 20, 2025 article are out of current scope. Scoring is constrained by coverage absence, not by demonstrated business weakness.

Thesis: Catalent also has material manufacturing-quality and scrutiny risk. Recent reporting cites six FOIA requests focused on Bloomington manufacturing issues and references FDA Form 483 observations tied to production problems, indicating persistent quality/regulatory overhang risk.

Why now: Positive developments cluster in April-June 2026, including Silexion GMP manufacturing initiation with Catalent on May 13, 2026

Caveats: Some negative items are undated within evidence and should be treated cautiously on exact recency. Sector-growth report evidence is supportive context, not company-specific performance proof. Context-only relation rows were not used as counterparty risk propagation.

Thesis: Risk edges higher because the available company-specific negative evidence includes removal from the NSE F&O segment effective April 29, 2026, while the reviewed sources' positive evidence is split across power utility and pharma contexts rather than a single clean peptide/API thesis.

Why now: Why now is mixed: CCI approval for Nabha Power came by early April and equity momentum peaked in late April, but the F&O exclusion also became effective on April 29, 2026, leaving a more balanced rather than one-sided setup

Caveats: Reviewed evidence for Torrent blends power utility and pharma group context; the peptide-manufacturing thesis is less direct than for several other names. Ticker provided refers to power entity context, while some cohort relevance depends on Torrent Pharma-related semaglutide articles.

Thesis: No direct adverse events are shown, but evidence sparsity and reliance on undated supplier-listing context make both upside and risk assessment uncertain.

Why now: The only retained support inside the recent evidence window is undated supplier-listing context naming Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical as a producer on a semaglutide API suppliers page

Caveats: Primary evidence is undated. The other named article is dated October 28, 2024 and therefore not useful for current-state recency. No direct company-specific milestone, contract, regulatory, or capacity event is in the reviewed sources.

Thesis: There is no direct adverse event evidence in the reviewed sources, but there is also no direct proof of commercial traction, approvals, expansion execution, or customer wins, leaving execution and durability uncertain. Risk is therefore mainly evidence-gap risk rather than documented business deterioration

Why now: The most recent dated context is a May 27, 2026 company webpage snapshot identifying the firm as a peptide R&D/production center, while the supplier-list evidence is undated, so recency on commercial status is only partly established, May 27, 2026, undated).

Caveats: No direct positive or negative events were available. Supplier-list and company-website context are weaker than company-specific operating events. One source is undated, so recency-sensitive claims are uncertain.

Thesis: No direct negative evidence is provided. Main risk is lack of current corroboration within the reviewed sources' retained recent evidence window evidence

Why now: There is no current why-now; the only supporting article is dated May 14, 2025 and was excluded by the 90-day recent evidence window

Caveats: Only stale supporting article context is available. No direct positive or negative evidence within the recent evidence window.

Thesis: No material adverse evidence is present inside the reviewed sources' recent evidence window. Risk score remains low because absence of current evidence is not itself negative, but stale evidence and zero in-recent evidence window rows raise uncertainty.

Why now: Why now is weak because the recent evidence review shows zero kept rows after the April 1, 2026 cutoff, meaning there is no current dated evidence to support either a fresh catalyst or an escalating problem.

Caveats: All dated company evidence is outside the 90-day recent evidence window. No direct positive or negative evidence survived recent evidence window. Company-site statements are older and not current-state proof for 1 year+ ranking.